Exatecan Mesylate, also known as DX-8951f, is a semisynthetic camptothecin-derived compound with antineoplastic activity. It is the methanesulfonate salt of exatecan and belongs to the class of topoisomerase I inhibitors.
Exatecan has been investigated for its potential use in oncology drug development. Its pharmacological activity is associated with interference in DNA replication and the induction of cancer-cell death. The compound is also relevant to research and development involving targeted anticancer drug delivery systems.
Exatecan Mesylate should be distinguished from exatecan free base and from its hydrated salt forms. The chemical form, water content, stereochemical identity and counterion composition must be confirmed before material acceptance.
The above formula and molecular weight refer to the anhydrous methanesulfonate salt. The dihydrate is a separate form with CAS 197720-53-9, formula C₂₅H₃₀FN₃O₉S and molecular weight 567.6 g/mol. <Cite refs={["turn341058search5","turn341058search8","turn341058search1"]}/>
Exatecan Mesylate inhibits DNA topoisomerase I by stabilising the cleavable complex formed between topoisomerase I and DNA. This prevents the normal re-ligation of DNA breaks during DNA replication.
The resulting accumulation of DNA damage interferes with DNA replication and can trigger apoptotic cell death. The National Cancer Institute describes exatecan mesylate as a semisynthetic, water-soluble camptothecin derivative with antineoplastic activity. <Cite refs={["turn341058search7","turn341058search1"]}/>
Exatecan Mesylate is supplied as a solid chemical material in research and development references. Its appearance, crystalline form, water content, solubility and stability should be confirmed against the actual supplied form and batch-specific certificate of analysis.
The anhydrous salt and dihydrate have different molecular weights and should not share an unqualified specification. Supplier-specific solubility and storage data should not be treated as universal pharmaceutical release requirements. <Cite refs={["turn341058search3","turn341058search5","turn341058search1"]}/>
Exatecan Mesylate is studied as an antineoplastic topoisomerase I inhibitor. Its chemical and pharmacological properties make it relevant to oncology research and pharmaceutical development.
Exatecan-related chemistry is also relevant to the development of antibody-drug conjugate (ADC) payloads. However, Exatecan Mesylate should not be confused with DXd or deruxtecan, which are distinct chemical entities. Their structures, linkers, payload characteristics and specifications are not interchangeable.
Quality assessment should be based on a product-specific approved specification and validated analytical procedures. Relevant quality attributes may include:
A research supplier's HPLC purity result is not automatically a pharmaceutical API release specification. No universal current IP, USP or Ph. Eur. monograph limits have been verified for this page. Numerical release limits should be established from validated methods, product-specific stability data and the approved quality specification.
Use suitable, tightly closed packaging that protects the material from moisture, contamination and unsuitable environmental conditions. Storage temperature, light protection, transport requirements and retest period must be established using product-specific stability data and the approved specification.
Some research suppliers specify frozen storage for their particular product presentation. Such supplier-specific conditions should not be applied universally to all Exatecan Mesylate batches. <Cite refs={["turn341058search9","turn341058search3"]}/>
Exatecan Mesylate is an antineoplastic research compound. Handle using appropriate containment, industrial hygiene and occupational safety controls suitable for potent cytotoxic materials. Avoid dust generation, inhalation and direct contact with skin and eyes. Use appropriate personal protective equipment and follow the current safety data sheet (SDS), site procedures and applicable hazardous-material handling requirements.
What is Exatecan Mesylate?
It is the methanesulfonate salt of exatecan, a camptothecin-derived topoisomerase I inhibitor.
What is the CAS number of Exatecan Mesylate?
The commonly referenced anhydrous salt has CAS number 169869-90-3.
What is its molecular formula?
The anhydrous salt is C₂₄H₂₂FN₃O₄·CH₄O₃S.
What is its molecular weight?
The anhydrous salt has a molecular weight of approximately 531.55 g/mol.
Is Exatecan Mesylate available as a hydrate?
Yes. A separately listed dihydrate form has CAS number 197720-53-9 and m
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder |
| Identification | IR and HPLC complaint |
| Assay (HPLC) | 99.0%–101.0% |
| Loss on Drying | NMT 6.0% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| Solubility | Freely soluble in water |